Aspirin can continue to reduce blood clot risk after anticoagulants for venous thromboembolism, study findsBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5300 (Published 26 August 2014) Cite this as: BMJ 2014;349:g5300
- Ingrid Torjesen
Aspirin should be considered as a follow-on treatment in patients who have finished a course of treatment with a vitamin K antagonist or a newer anticoagulant after venous thromboembolism, to continue to reduce their risk of further blood clots, research published in Circulation has found.1
Patients who have venous thromboembolism with no obvious cause have an average 10% risk of another clot within one year and a 5% risk each year thereafter. After the event patients usually receive warfarin or a newer anticoagulant for six to 12 months …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial